The MOUNTAINEER trial, a global, open-label, phase 2 study, enrolled patients with HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer to evaluate the effectiveness of combining tucatinib with trastuzumab, both of which target HER2. Here, ERBB2 is linked to metastatic colorectal cancer.